Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200032, China
NCT Number: NCT06319300
Our study was a single-blind, randomised, controlled, multicentre study. The study was planned to enrol 142 patients with T2DM admitted to general wards who required subcutaneous insulin therapy. Participants were randomly divided into two groups in the ratio of 1:1, one group with an artificial intelligence-assisted insulin decision system to adjust insulin doses for blood glucose control, and the other group received clinician-instituted insulin dose adjustments for blood glucose control. The effectiveness and safety of the system was confirmed by comparing the glycaemic control and risk of adverse events between the two groups.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Shanghai, Shanghai Municipality, 200032, China
Our study was a single-blind, randomised, controlled, multicentre study. The study was planned to enrol 142 patients with T2DM admitted to the general ward who required subcutaneous insulin therapy. Participants were randomly divided into two groups in the ratio of 1:1, one group with an artificial intelligence-assisted insulin decision system to adjust insulin doses for blood glucose control, and the other group received clinician-instituted insulin dose adjustments for blood glucose control. The effectiveness and safety of the system was confirmed by comparing the glycaemic control and risk of adverse events between the two groups.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
We use an artificial intelligence-assisted insulin dose adjustment system to adjust insulin doses in hospitalised patients
Other names: the Artificial Intelligence-assisted Insulin Dose Adjustment System
participants' insulin doses are adjusted by doctors
Time frame: ≥3 days
Proportion of time in the target glucose range (TIR; 3.9-10.0 mmol/L) measured by CGM during the intervention period.
Time frame: ≥3 days
Proportion of time during which sensor glucose levels are within the ranges (5.6-10.0mmol/L,10.1-13.9mmol/L, >13.9mmol/L,<3.0mmol/L, 3.0-3.8mmol/L), as measured by CGM during the intervention period
Time frame: ≥3 days
pre-breakfast, pre-lunch, pre-dinner, pre-bedtime
Time frame: ≥3 days
capillary blood glucose<3.9 mmol/L, <3.0 mmol/L, < 2.2 mmol/L or an episode that requires of assistance of another person
Time frame: ≥3 days
capillary blood glucose>20.0 mmol/L, and/or ketoacidosis, and/or hyperosmotic status.
Time frame: ≥3 days
insulin dosage
Time frame: after intervention
evaluated by questionnaire.
Time frame: ≥3 days
Length of hospitalisation
Time frame: ≥3 days
Itchy skin, admission to ICU, death, etc.
Shanghai Zhongshan Hospital
Other
Efficacy and Safety of the Artificial Intelligence-assisted Insulin Dose Adjustment System for Glycaemic Control in Patients With Type 2 Diabetes Mellitus in General Wards: a Multicentre, Single-blind, Randomised Controlled Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06912542
Diabetes, Diabetes Mellitus
Santa Maria, Rio Grande do Sul, Brazil
View Trial DetailsNCT05031572
Behavior, Body Weight
Tarragona, Spain
View Trial DetailsNCT00898950
Diabetes Mellitus, Diabetes Mellitus, Type 2
Portsmouth, Hampshire, United Kingdom
View Trial DetailsNCT02107976
Diabetes Mellitus, Diabetes Mellitus, Type 2
Bethesda, Maryland, United States
View Trial Details